219 related articles for article (PubMed ID: 32714184)
21. Dose individualization of intravenous busulfan in pediatric patients undergoing bone marrow transplantation: impact and in vitro evaluation of infusion lag-time.
Neroutsos E; Athanasiadou I; Paisiou A; Zisaki K; Goussetis E; Archontaki H; Tsirigotis P; Kitra M; Grafakos S; Spyridonidis A; Dokoumetzidis A; Valsami G
J Pharm Pharmacol; 2021 Sep; 73(10):1340-1350. PubMed ID: 34244783
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation.
Lawson R; Paterson L; Fraser CJ; Hennig S
Cancer Chemother Pharmacol; 2021 Sep; 88(3):379-391. PubMed ID: 34021809
[TBL] [Abstract][Full Text] [Related]
23. Busulfan dosing in children with BMIs ≥ 85% undergoing HSCT: a new optimal strategy.
Browning B; Thormann K; Donaldson A; Halverson T; Shinkle M; Kletzel M
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1383-8. PubMed ID: 21288495
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients.
Zhu J; Campagne O; Torrice CD; Flynn G; Miller JA; Patel T; Suzuki O; Ptachcinski JR; Armistead PM; Wiltshire T; Mager DE; Weiner DL; Crona DJ
Clin Transl Sci; 2021 May; 14(3):908-918. PubMed ID: 33502111
[TBL] [Abstract][Full Text] [Related]
25. New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning.
Poinsignon V; Faivre L; Nguyen L; Neven B; Broutin S; Moshous D; Bourget P; Dufour C; Dalle JH; Galambrun C; Devictor B; Kemmel V; De Berranger E; Gandemer V; Vannier JP; Jubert C; Bondu S; Mir O; Petain A; Vassal G; Paci A
Pediatr Blood Cancer; 2020 Oct; 67(10):e28603. PubMed ID: 32706505
[TBL] [Abstract][Full Text] [Related]
26. Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children.
Philippe M; Goutelle S; Guitton J; Fonrose X; Bergeron C; Girard P; Bertrand Y; Bleyzac N
Bone Marrow Transplant; 2016 Jan; 51(1):72-8. PubMed ID: 26389835
[TBL] [Abstract][Full Text] [Related]
27. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan.
Chen RL; Fang LH; Yang XY; El Amrani M; Uijtendaal EV; Chen YF; Ku WC
Pharmaceuticals (Basel); 2021 Jun; 14(7):. PubMed ID: 34206798
[TBL] [Abstract][Full Text] [Related]
29. Dosing algorithm revisit for busulfan following IV infusion.
Wang Y; Kato K; Le Gallo C; Armstrong E; Rock E; Wang X
Cancer Chemother Pharmacol; 2015 Mar; 75(3):505-12. PubMed ID: 25561350
[TBL] [Abstract][Full Text] [Related]
30. Costs and Outcomes with Once-Daily versus Every-6-Hour Intravenous Busulfan in Allogeneic Hematopoietic Cell Transplantation.
Singhal S; Kim T; Jenkins P; Bassett B; Tierney DK; Rezvani AR
Biol Blood Marrow Transplant; 2020 Jan; 26(1):145-149. PubMed ID: 31525492
[TBL] [Abstract][Full Text] [Related]
31. Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?
Brooks KM; Jarosinski P; Hughes T; Kang E; Shah NN; Gall JBL; Hickstein DD; De Ravin SS; George JM; Kumar P
J Clin Pharmacol; 2018 Mar; 58(3):332-339. PubMed ID: 29238995
[TBL] [Abstract][Full Text] [Related]
32. Optimization of Busulfan Dosing Regimen in Pediatric Patients Using a Population Pharmacokinetic Model Incorporating GST Mutations.
Yuan J; Sun N; Feng X; He H; Mei D; Zhu G; Zhao L
Pharmgenomics Pers Med; 2021; 14():253-268. PubMed ID: 33623415
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
Paci A; Vassal G; Moshous D; Dalle JH; Bleyzac N; Neven B; Galambrun C; Kemmel V; Abdi ZD; Broutin S; Pétain A; Nguyen L
Ther Drug Monit; 2012 Apr; 34(2):198-208. PubMed ID: 22406655
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance.
Choong E; Uppugunduri CRS; Marino D; Kuntzinger M; Doffey-Lazeyras F; Lo Piccolo R; Chalandon Y; Peters C; Daali Y; Ansari M
Ther Drug Monit; 2018 Feb; 40(1):84-92. PubMed ID: 29189665
[TBL] [Abstract][Full Text] [Related]
35. Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation.
Ward J; Kletzel M; Duerst R; Fuleihan R; Chaudhury S; Schneiderman J; Tse WT
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1612-21. PubMed ID: 26025482
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic drug monitoring of intravenous busulfan in Thai children undergoing hematopoietic stem cell transplantation: A pilot study.
Jansing T; Sanpakit K; Tharnpanich T; Jiranantakan T; Niphandwongkorn V; Chindavijak B; Suansanae T
Pediatr Hematol Oncol; 2021 May; 38(4):346-357. PubMed ID: 33656974
[TBL] [Abstract][Full Text] [Related]
37. Clinical consequences of analytical variance and calculation strategy in oral busulfan pharmacokinetics.
Olson MT; Lombardi L; Clarke W
Clin Chim Acta; 2011 Nov; 412(23-24):2316-21. PubMed ID: 21906584
[TBL] [Abstract][Full Text] [Related]
38. Can First-Dose Therapeutic Drug Monitoring Predict the Steady State Area Under the Blood Concentration-Time Curve of Busulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation?
Alsultan A; Albassam AA; Alturki A; Alsultan A; Essa M; Almuzzaini B; Alfadhel S
Front Pediatr; 2022; 10():834773. PubMed ID: 35463912
[TBL] [Abstract][Full Text] [Related]
39. Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions.
Combarel D; Tran J; Delahousse J; Vassal G; Paci A
Expert Opin Drug Metab Toxicol; 2023 Feb; 19(2):75-90. PubMed ID: 36939456
[TBL] [Abstract][Full Text] [Related]
40. Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.
McCune JS; Bemer MJ; Barrett JS; Scott Baker K; Gamis AS; Holford NH
Clin Cancer Res; 2014 Feb; 20(3):754-63. PubMed ID: 24218510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
